IRX Therapeutics to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference

NEW YORK--()--IRX Therapeutics, Inc. (IRX) today announced that Mark Leuchtenberger, the Company’s President and Chief Executive Officer, will present a corporate overview at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m. Eastern time. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.

About IRX Therapeutics

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, to recognize and destroy tumors. For more information about the Company and its clinical programs, please visit www.IRXTherapeutics.com.

Contacts

Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com

Release Summary

IRX today announced that Mark Leuchtenberger, President and CEO, will present a corporate overview at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on April 7 at 3 PM.

Contacts

Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com